These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25512257)

  • 1. SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.
    Yeh YW; Chen CJ; Jang FL; Kuo SC; Chen CY; Liang CS; Ho PS; Yen CH; Shyu JF; Wan FJ; Lu RB; Huang SY
    J Psychiatr Res; 2015 Feb; 61():33-9. PubMed ID: 25512257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP1A2 Genetic Polymorphism Is Associated With Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population.
    Zhu Y; Zhang N; Ren D; Bi Y; Xu F; Niu W; Sun Q; Guo Z; Yuan R; Yuan F; Wu X; Cao Y; Yang F; Wang L; Du L; Li W; Xu Y; Li X; Zhu L; He L; Shi L; He G; Yu T
    Clin Neuropharmacol; 2019; 42(2):32-36. PubMed ID: 30875344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population.
    Zhang N; Ji L; Chen Z; An L; Ren D; Bi Y; Guo Z; Yuan R; Yuan F; Dong Z; Yin L; Sun X; Yang F; Li X; Yu T; He L; Shi L; He G
    Psychiatr Genet; 2020 Feb; 30(1):30-33. PubMed ID: 31842058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.
    Marshe VS; Maciukiewicz M; Rej S; Tiwari AK; Sibille E; Blumberger DM; Karp JF; Lenze EJ; Reynolds CF; Kennedy JL; Mulsant BH; Müller DJ
    Am J Psychiatry; 2017 May; 174(5):468-475. PubMed ID: 28068779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.
    Proft F; Kopf J; Olmes D; Hempel S; Schmidt B; Riederer P; Deckert J; Pfuhlmann B; Reif A; Unterecker S
    Pharmacopsychiatry; 2014 Nov; 47(7):245-50. PubMed ID: 25295552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression.
    Yin L; Zhang YY; Zhang X; Yu T; He G; Sun XL
    Pharmacopsychiatry; 2015 May; 48(3):95-103. PubMed ID: 25642918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between norepinephrine transporter gene (SLC6A2) polymorphisms and suicide in patients with major depressive disorder.
    Kim YK; Hwang JA; Lee HJ; Yoon HK; Ko YH; Lee BH; Jung HY; Hahn SW; Na KS
    J Affect Disord; 2014 Apr; 158():127-32. PubMed ID: 24655776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No Association Between SLC6A4 Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients.
    Wu N; Liu L; Ren D; Yuan F; Bi Y; Guo Z; Hou B; Ji L; Han K; Feng M; Su K; Yu T; Li X; Yang F; Sun X; Dong Z; Yu S; Yi Z; Xu Y; He L; Wu S; Zhao L; Changqun C; Shi Y; He G
    Clin Neuropharmacol; 2021 Mar-Apr 01; 44(2):53-56. PubMed ID: 33480616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    Entsuah AR; Huang H; Thase ME
    J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A possible association of the norepinephrine transporter gene in the development of heroin dependence in Han Chinese.
    Yeh YW; Lu RB; Tao PL; Shih MC; Huang SY
    Pharmacogenet Genomics; 2011 Apr; 21(4):197-205. PubMed ID: 20818294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.
    Wang HC; Yeh TL; Chang HH; Gean PW; Chi MH; Yang YK; Lu RB; Chen PS
    Psychopharmacology (Berl); 2011 Feb; 213(4):773-9. PubMed ID: 20945066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan.
    Wu YS; Chen YC; Lu RB
    J Clin Pharm Ther; 2007 Aug; 32(4):353-63. PubMed ID: 17635337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine.
    Lee SH; Choi TK; Lee E; Seok JH; Lee SH; Lee HS; Kim SJ
    Neuropsychobiology; 2010 Aug; 62(3):198-206. PubMed ID: 20664233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.
    Shea ML; Garfield LD; Teitelbaum S; Civitelli R; Mulsant BH; Reynolds CF; Dixon D; Doré P; Lenze EJ
    Osteoporos Int; 2013 May; 24(5):1741-9. PubMed ID: 23358607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
    Vis PM; van Baardewijk M; Einarson TR
    Ann Pharmacother; 2005 Nov; 39(11):1798-807. PubMed ID: 16189284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Response and remission in depressive patients with anxiety symptoms treated with venlafaxine extended release in primary care].
    Roca Benassar M; Baca Baldomero E
    Actas Esp Psiquiatr; 2006; 34(3):162-8. PubMed ID: 16736389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.